

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: AI/ML Innovations Inc. (the "Issuer").

Trading Symbol: AIML

Number of Outstanding Listed Securities: 63,372,397

Date: 7/11/2023

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer continued to advance its business operations on multiple fronts. Its majority owned subsidiary, Health Gauge, was active in developing additional business relationships and continued development work of its apps and cloud solutions, including custom work for a strategic partner – MedWatch for which Health Gauge is actively involved in the development of MedWatch products and

services. [Note: there is a non-arm's length component to the relationship as the Issuer and MedWatch share a common Officer/Director].

The issuer's minority-owned subsidiary, Tech2Heal, continued business development for its Remote Patient Monitoring Platform (Alakin) and its flagship Qookka mental wellness platform, as well as the implementation of certain feature sets required by potential customers, and readying for several pilot studies.

2. Provide a general overview and discussion of the activities of management.

During the month, management was engaged in business development activities for its various products. It also furthered its discussions with potential channel partners and other potential users of the Health Gauge technology. Consulting work with MedWatch continued by the Health Gauge management towards the advancement of MedWatch's blood glucose monitoring device.

Additionally, the Issuer was actively preparing for the upcoming AGM scheduled for November.

Finally, management was active in settling outstanding debt with a creditor. As reported by the Issuer on October 11, 2023, the Issuer announced that it has entered into a Debt Settlement Agreement with Tormin Resources Limited of Roslin, Ontario (the "Creditor"). The Company owes the Creditor an aggregate amount of \$733,441, plus \$68,500 in accrued fees, for a total amount of \$801,941.00 (the "Debt") pursuant to a loan. The Company and the Creditor have entered into a Debt Settlement Agreement dated October 11, 2023, wherein the Creditor has agreed to accept a cash payment of \$70,000 in full and complete settlement of the debt.

3. Describe and provide details of any new products or services developed or offered.

None.

4. Describe and provide details of any products or services that were discontinued.

None.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

On October 18, 2023, the Issuer reported that its minority-owned subsidiary, Tech2Heal SAS from Paris, France, has announced the following:

Tech2heal, a leading innovator of digital healthcare solutions, is thrilled to announce its latest milestone - securing its second clinical trial contract. This time for a groundbreaking clinical trial project named "My Health Friend", a symbol of cross-border cooperation between France and Italy in the realm of preventative health care. Tech2Heal's proprietary Alakin Platform, a highly adaptable care pathway builder, has been chosen as the digital backbone for this pioneering trial that is set to commence in May of 2024. At the heart of the trial is the innovative,

multi-language My Health Friend mobile health application, designed to enhance the well-being of a targeted cross-border population through personalized digital rehabilitation - ultimately striving to mitigate the socio-health and economic impact of chronic diseases within geographical regions that have limited access to in-person health care.

Additionally, on October 19, 2023, the Issuer announced its minority-owned subsidiary, Tech2Heal SAS, reported its pivotal participation in a distinguished consortium, anchored by Essilor International (a division of EssilorLuxottica - the largest single player in the global eyewear market). This consortium represents an extraordinary convergence of cross-functional experts spanning the entire value chain, comprising 11 esteemed partner organizations hailing from four EU countries.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None.

8. Describe the acquisition of new customers or loss of customers.

None.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

As reported by the Issuer on October 11, 2023, the Issuer announced that it has entered into a Debt Settlement Agreement with Tormin Resources Limited of Roslin, Ontario (the "Creditor"). The Company owes the Creditor an aggregate amount of \$733,441, plus \$68,500 in accrued fees, for a total amount of \$801,941.00 (the "Debt") pursuant to a loan. The Company and the Creditor have entered into a Debt Settlement Agreement dated October 11, 2023, wherein the Creditor has agreed to accept a cash payment of \$70,000 in full and complete settlement of the debt.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds
shares	450,000	Exercise of \$0.10 warrants	Working capital

15. Provide details of any loans to or by Related Persons.

None.

16. Provide details of any changes in directors, officers or committee members.

None.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

There is a growing awareness and acceptance amongst the public, healthcare providers, insurers/payors, and regulators towards the use of digital and virtual healthcare in general, with mental healthcare making up an increasing component of that. This trend is expected to continue at double digit growth rates globally for the next several years. Its acceptance was expedited by the CV-19 pandemic as patients were discouraged from face-to-face medical intervention in all but the most dire of circumstances. The general public has grown to understand the ease and convenience of digital healthcare as a result and healthcare payors understand that the deployment of digital health solutions both improves outcomes and reduces costs. Governments across Europe are implementing laws requiring payors to cover the cost of digital mental health therapy to the same extent as conventional methods.

Additionally, with the recent advancements in artificial intelligence and the general public's awareness of same, investors and strategic partners are showing a keen and growing interest in sourcing investments in the AI space. Predictions show that AI will have a multi trillion-dollar impact on the global economies and effect almost all facets of modern society. As this is the core business of the Issuer, we expect

to benefit positively and significantly, both in terms of investor awareness as well as business development opportunities from this generational event.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated 7/11/2023

Tim Daniels
Name of Director or Senior
Officer

/S/ "Tim Daniels"
Signature
Executive Chairman
Official Capacity

Issuer Details Name of Issuer AI/ML Innovations Inc.	For Month End October 2023	Date of Report YY/MM/D 23/11/07
Issuer Address Suite 203, 645 Fort St.		
City/Province/Postal Code Victoria, BC V8W 1G2	Issuer Fax No.	Issuer Telephone No. (778) 405-0882
Contact Name Tim Daniels	Contact Position Director	Contact Telephone No. 250 483-5650
Contact Email Address tim.daniels@aiml-innovations.com	Web Site Address aiml-innovations.com	